<?xml version='1.0' encoding='utf-8'?>
<document id="19499965"><sentence text="Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient."><entity charOffset="74-84" id="DDI-PubMed.19499965.s1.e0" text="everolimus" /><entity charOffset="89-94" id="DDI-PubMed.19499965.s1.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.19499965.s1.e0" e2="DDI-PubMed.19499965.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19499965.s1.e0" e2="DDI-PubMed.19499965.s1.e1" /></sentence><sentence text="We report a case of a 54-year-old male renal transplant patient who received antifungal azole treatment in combination with the recently introduced immunosuppressant agent everolimus to prevent post-transplantation aspergillosis reactivation"><entity charOffset="88-93" id="DDI-PubMed.19499965.s2.e0" text="azole" /><entity charOffset="172-182" id="DDI-PubMed.19499965.s2.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.19499965.s2.e0" e2="DDI-PubMed.19499965.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19499965.s2.e0" e2="DDI-PubMed.19499965.s2.e1" /></sentence><sentence text=" Voriconazole was withdrawn after 1 month because of elevated concentrations (5 mg/L trough plasma determination) and hepatotoxicity, and substituted by several months of treatment with posaconazole (observed concentration range 1-2 mg/L)"><entity charOffset="1-13" id="DDI-PubMed.19499965.s3.e0" text="Voriconazole" /><entity charOffset="186-198" id="DDI-PubMed.19499965.s3.e1" text="posaconazole" /><entity charOffset="8-19" id="DDI-PubMed.19499965.s3.e2" text="azole" /><entity charOffset="193-204" id="DDI-PubMed.19499965.s3.e3" text="azole" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e0" e2="DDI-PubMed.19499965.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e0" e2="DDI-PubMed.19499965.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e0" e2="DDI-PubMed.19499965.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e0" e2="DDI-PubMed.19499965.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e2" e2="DDI-PubMed.19499965.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e2" e2="DDI-PubMed.19499965.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e2" e2="DDI-PubMed.19499965.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e1" e2="DDI-PubMed.19499965.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s3.e1" e2="DDI-PubMed.19499965.s3.e3" /></sentence><sentence text=" We observed pharmacokinetic drug interactions between both voriconazole and posaconazole, and everolimus cytochrome P450 3A4 metabolism, resulting in 7"><entity charOffset="60-72" id="DDI-PubMed.19499965.s4.e0" text="voriconazole" /><entity charOffset="77-89" id="DDI-PubMed.19499965.s4.e1" text="posaconazole" /><entity charOffset="95-105" id="DDI-PubMed.19499965.s4.e2" text="everolimus" /><entity charOffset="67-76" id="DDI-PubMed.19499965.s4.e3" text="azole" /><entity charOffset="84-93" id="DDI-PubMed.19499965.s4.e4" text="azole" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e0" e2="DDI-PubMed.19499965.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e0" e2="DDI-PubMed.19499965.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e0" e2="DDI-PubMed.19499965.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e0" e2="DDI-PubMed.19499965.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e0" e2="DDI-PubMed.19499965.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e3" e2="DDI-PubMed.19499965.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e3" e2="DDI-PubMed.19499965.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e3" e2="DDI-PubMed.19499965.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e3" e2="DDI-PubMed.19499965.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e1" e2="DDI-PubMed.19499965.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e1" e2="DDI-PubMed.19499965.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e1" e2="DDI-PubMed.19499965.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e4" e2="DDI-PubMed.19499965.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19499965.s4.e4" e2="DDI-PubMed.19499965.s4.e2" /></sentence><sentence text="5- and 3" /><sentence text="8-fold increase, respectively, in everolimus blood trough concentrations" /><sentence text=" Combined therapeutic drug monitoring (TDM) of both everolimus and azole inhibitors allowed for safe and convenient modification of everolimus dosage, which was tapered to maintain a target range of 5-15 ng/mL during and after antifungal treatments"><entity charOffset="52-62" id="DDI-PubMed.19499965.s7.e0" text="everolimus" /><entity charOffset="67-72" id="DDI-PubMed.19499965.s7.e1" text="azole" /><entity charOffset="132-142" id="DDI-PubMed.19499965.s7.e2" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.19499965.s7.e0" e2="DDI-PubMed.19499965.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19499965.s7.e0" e2="DDI-PubMed.19499965.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s7.e0" e2="DDI-PubMed.19499965.s7.e2" /><pair ddi="false" e1="DDI-PubMed.19499965.s7.e1" e2="DDI-PubMed.19499965.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19499965.s7.e1" e2="DDI-PubMed.19499965.s7.e2" /></sentence><sentence text=" While significant in their effects, these drug interactions were able to be managed safely through a careful approach to management and use of individual TDM" /><sentence text="" /></document>